616 related articles for article (PubMed ID: 32000827)
21. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
22. Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.
Ma L; Liu W; Xu A; Ji Q; Ma Y; Tai Y; Wang Y; Shen C; Liu Y; Wang T; Han J; Zhao C
Cancer Sci; 2020 Jun; 111(6):2028-2040. PubMed ID: 32279388
[TBL] [Abstract][Full Text] [Related]
23. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
24. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
[No Abstract] [Full Text] [Related]
25. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
26. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
27. Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway.
Luo J; Sun P; Zhang X; Lin G; Xin Q; Niu Y; Chen Y; Xu N; Zhang Y; Xie W
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948132
[TBL] [Abstract][Full Text] [Related]
28. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis.
Hua Q; Mi B; Xu F; Wen J; Zhao L; Liu J; Huang G
Theranostics; 2020; 10(11):4762-4778. PubMed ID: 32308748
[No Abstract] [Full Text] [Related]
30. Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7.
Yousef EH; Abo El-Magd NF; El Gayar AM
Life Sci; 2023 Jul; 324():121735. PubMed ID: 37142088
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
[TBL] [Abstract][Full Text] [Related]
32. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
Yin F; Feng F; Wang L; Wang X; Li Z; Cao Y
Cell Death Dis; 2019 Sep; 10(9):672. PubMed ID: 31511501
[TBL] [Abstract][Full Text] [Related]
33. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
Jiao M; Nan KJ
Int J Oncol; 2012 Feb; 40(2):461-8. PubMed ID: 21922131
[TBL] [Abstract][Full Text] [Related]
34. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
36. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
37. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
38. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
[TBL] [Abstract][Full Text] [Related]
39. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
[TBL] [Abstract][Full Text] [Related]
40. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
